Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

of additional higher doses of LX2931 as an orally-delivered treatment for rheumatoid arthritis," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "While we were disappointed by the unusually high placebo effect in this trial, we are encouraged by the excellent overall safety profile observed in the first test of this new mechanism of action in patients with RA."  

The company intends to commence discussions with potential pharmaceutical partners to pursue further development of LX2931 in rheumatoid arthritis.

Clinical Trial

The recently completed study was a 12-week, randomized, double-blind, placebo-controlled study in 208 patients on stable dose methotrexate with progressing rheumatoid arthritis. Patients were randomized to receive either placebo (n=49) or LX2931, 70 mg (n=55), 110 mg (n=54), or 150 mg (n=50), once daily for 12 weeks.  In addition to measurements to assess the drug's safety, efficacy endpoints included the primary endpoint, ACR20 at week 12, as well as secondary endpoints of ACR20, ACR50, ACR70 and DAS28 at weeks 4, 8 and 12.  The trial was conducted at sites within the United States and Eastern Europe.

About S1P Lyase and the Role of S1P in Autoimmune Disease

S1P lyase is responsible for the irreversible degradation of S1P, a biologically active lipid that can act as a second messenger in signal transduction pathways important for immune function.  Changes in local S1P concentrations and gradients in immune tissues can modify lymphocyte migration, inflammatory cell response, and affect barrier function of endothelial cells.  Inhibiting S1P lyase results in an increase in S1P levels, primarily in lymphoid tissues.  The physiological outcome of raising S1P levels in the lymphoid system is immune-modulation, which offers new opportunities for treating autoimmune and inflammatory
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
(Date:6/29/2015)... -- Allergan plc (NYSE: AGN ) today announced ... financial results on Thursday, August 6, 2015, prior ... Company will host a conference call and webcast ... August 6, 2015 to discuss its financial results. The ... Canada (877) 251-7980, International (706) ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 2Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced financial results for the quarter ... in this press release should be read in ...
... Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a ... equipment to medical institutions, announced today that Encore ... significant growth from Encore Medical Staffing operations in ... started this franchise in December, 2010," says Dr. ...
Cached Medicine Technology:Dyadic International Reports 2011 First Quarter Financial Results 2Dyadic International Reports 2011 First Quarter Financial Results 3Dyadic International Reports 2011 First Quarter Financial Results 4Dyadic International Reports 2011 First Quarter Financial Results 5Southern Home Medical Equipment Reports Significant Growth from Encore Franchisees 2
(Date:6/30/2015)... , ... June 30, 2015 ... ... the drug response profiling test to help oncologists provide personalized cancer treatment, ... “The CorrectChemo® assay provides the oncologist with valuable insight on how a ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... has joined Allegheny Health Network (AHN) as Director of its Adult ... management of primary brain tumors, brain metastases, leptomeningeal disease and the neurological complications ...
(Date:6/30/2015)... ... June 30, 2015 , ... Harbor Village Detox is a ... in Florida on June 12th. Holly Vasquez-Cortella was recently quoted as an expert ... dedicated to reporting on trending addiction news and treatment innovations. The article highlights Florida ...
(Date:6/30/2015)... ... June 30, 2015 , ... Under Armour’s ... at less thickness than any other padding in football. , Developed in partnership ... shock absorption, Gameday Armour is engineered with D3O protective polymer. This radical polymer ...
(Date:6/30/2015)... ... June 30, 2015 , ... It has become fairly common to purchase fresh ... discard the stalks before cooking. Throwing out radish greens, beet leaves and chard stalks ... delicious. It just takes a little knowledge and practice to use them. Josie's ...
Breaking Medicine News(10 mins):Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4
... and outstanding achievement in applied medical ... ... 11 Siemens Medical,Solutions (http://www.usa.siemens.com/healthcareit ) congratulates Dr. Kenneth ... on receiving one of the 2007 Association of,Medical Directors of ...
... Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... has posted an exclusive interview with Crdentia,s ... Audiostocks.com website. In the interview, Ms. ... and plans for short-term and long-term,strategic growth. ...
... Annual Premiums for Family Coverage Now Average $12,106, ... Health Plans Remains Modest, WASHINGTON, Sept. 11 ... of 6.1 percent in 2007,less than the 7.7 ... than,the increase in workers, wages (3.7 percent) or ...
... BOSTON, Mass. (September 11, 2007)Uninsured patients in publicly funded ... outside of these centers, a new study finds. Whats ... has determined that the patient does in fact need ... insurance have a relatively easier time accessing services. ...
... In what is being described as an "unexpected finding," ... and complications with acute appendicitis. The study, which will ... of the American College of Surgeons, found that uninsured ... increased likelihood of perforation, or rupture, of the appendix ...
... Research here shows that an obscure form of RNA, part ... important role in human cancer. , These ultraconserved non-coding ... a new report in the September issue of the journal ... , The study found that UCRs, like classic oncogenes, ...
Cached Medicine News:Health News:Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award 2Health News:Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award 3Health News:Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award 4Health News:Crdentia's VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy 2Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 2Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 3Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 4Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 5Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 6Health News:Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation 7Health News:Uninsured community health center patients often have difficulty accessing specialty services 2Health News:Uninsured community health center patients often have difficulty accessing specialty services 3Health News:Study shows insurance status, not race, linked to complications in patients with acute appendicitis 2Health News:New class of RNA molecules may be important in human cancer 2
... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
Medicine Products: